Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Invested Capital (2022 - 2025)

Taysha Gene Therapies' Invested Capital history spans 4 years, with the latest figure at $219.0 million for Q3 2025.

  • For Q3 2025, Invested Capital rose 146.62% year-over-year to $219.0 million; the TTM value through Sep 2025 reached $219.0 million, up 146.62%, while the annual FY2024 figure was $111.5 million, 48.83% up from the prior year.
  • Invested Capital for Q3 2025 was $219.0 million at Taysha Gene Therapies, down from $248.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $248.7 million in Q2 2025 and bottomed at -$37.1 million in Q2 2023.
  • The 4-year median for Invested Capital is $53.8 million (2024), against an average of $66.3 million.
  • The largest YoY upside for Invested Capital was 7796.42% in 2023 against a maximum downside of 214.17% in 2023.
  • A 4-year view of Invested Capital shows it stood at $949000.0 in 2022, then skyrocketed by 7796.42% to $74.9 million in 2023, then soared by 48.83% to $111.5 million in 2024, then surged by 96.36% to $219.0 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Invested Capital are $219.0 million (Q3 2025), $248.7 million (Q2 2025), and $55.1 million (Q1 2025).